BriaCell Therapeutics Corp. (BCT.TO)
| Previous Close | 9.58 |
| Open | 9.80 |
| Bid | 10.03 x N/A |
| Ask | 10.09 x N/A |
| Day's Range | 9.74 - 10.08 |
| 52 Week Range | 5.32 - 15.05 |
| Volume | |
| Avg. Volume | 12,237 |
| Market Cap | 155.646M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | 1,003.00 |
| EPS (TTM) | 0.01 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- GlobeNewswire
BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already Held
SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer.SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announc
- Baystreet
Stocks in play: BriaCell Therapeutics Corp
Has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) ...
- GlobeNewswire
BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando, Florida. The available abstract titles and
